Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: Data from the reduction of atherothrombosis for continued health (REACH) registry

European Journal of Vascular and Endovascular Surgery

Volumn 40, Issue 1, 2010, Pages 9-16

  Winkel, T A ^a   Hoeks, S E ^a   Schouten, O ^b   Zeymer, U ^c   Limbourg, T ^c   Baumgartner, I ^d   Bhatt, D L ^e   Steg, P G ^f   Goto, S ^g   Rother J ^h   Cacoub, P P ⁱ   Verhagen, H J M ^a   Bax, J J ^j   Poldermans, D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d BERN UNIVERSITY HOSPITAL   (Switzerland)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f INSERM   (France)

^g TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KLINIKUM MINDEN   (Germany)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Atrial fibrillation; Prognosis; REACH Registry

Indexed keywords

AGED; ARTERY DISEASE; ARTICLE; ATHEROTHROMBOSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; EUROPE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RISK FACTOR; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 77954312068     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2010.03.003     Document Type: Article

References (32)

1. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 2004;93(11):1422-5. A10.
2. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002;13(Suppl. 1):1-6.
3. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295(2):180-9.
4. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156(5):855-63. p. 63 -2.
5. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol 2000;23(Suppl. 6):VI-18-VI-22.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-5.
7. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48(4):854-906.
8. Lane DA, Lip GY. Quality of life in older people with atrial fibrillation. J Interv Card Electrophysiol 2009;25(1):37-42.
9. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14(6):666-72.
10. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic eventsstudy design. Am Heart J 2006;151(4)(786):e1-10.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
12. Frykman V, Frick M, Jensen-Urstad M, Ostergren J, Rosenqvist M. Asymptomatic versus symptomatic persistent atrial fibrillation: Clinical and noninvasive characteristics. J Intern Med 2001;250(5):390-7.
13. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009;30(2):192-201.
14. Steg PG, Bhatt DL, Wilson PW, D'Agostino Sr R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297(11):1197-206.
15. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155(5):469-73.
16. Ouriel K. Peripheral arterial disease. Lancet 2001;358(9289): 1257-64.
17. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840-4.
18. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006;166(21):2322-8.
19. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med 2005;118(5):489-95. (Pubitemid 40615472)
20. Aberg H. Atrial fibrillation. A review of 463 cases from Philadelphia General Hospital from 1955 to 1965. Acta Med Scand 1968;184(5):425-31.
21. Davidson E, Weinberger I, Rotenberg Z, Fuchs J, Agmon J. Atrial fibrillation. Cause and time of onset. Arch Intern Med 1989; 149(2):457-9.
22. Petersen P, Godtfredsen J. Atrial fibrillation-a review of course and prognosis. Acta Med Scand 1984;216(1):5-9.
23. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: The Copenhagen City Heart Study. Circulation 2005; 112(12):1736-42.
24. Kozlowski D, Budrejko S, Lip GY, Rysz L, Mikhailidis DP, Raczak G, et al. Lone atrial fibrillation - what do we know? Heart 2010;96:498-503.
25. Laguna P, Martin A, Del Arco C, Millan I, Gargantilla P. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: Implications for therapy in daily practice. Acad Emerg Med 2005;12(9):828-34.
26. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Bourassa MG, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358(25):2667-77.
27. Holmes Jr DR, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009;54(2):95-109.
28. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357(3):217-27.
29. The effects of oral anticoagulants in patients with peripheral arterial disease: Rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J 2006; 151(1):1-9.
30. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54(11): 999-1002.
31. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.
32. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter- Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11):e463-e654.